WO2010033481A1 - Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide - Google Patents

Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide Download PDF

Info

Publication number
WO2010033481A1
WO2010033481A1 PCT/US2009/056918 US2009056918W WO2010033481A1 WO 2010033481 A1 WO2010033481 A1 WO 2010033481A1 US 2009056918 W US2009056918 W US 2009056918W WO 2010033481 A1 WO2010033481 A1 WO 2010033481A1
Authority
WO
WIPO (PCT)
Prior art keywords
salt
methyl
biphenyl
cis
carboxamide
Prior art date
Application number
PCT/US2009/056918
Other languages
French (fr)
Inventor
Joginder Singh Bajwa
Marilyn De La Cruz
Stephanie Kay Dodd
Liladhar Murlidhar Waykole
Raeann Wu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010033481(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BRPI0918629A priority Critical patent/BRPI0918629B8/en
Priority to NZ591420A priority patent/NZ591420A/en
Priority to EP09792531A priority patent/EP2342198B1/en
Priority to AU2009293444A priority patent/AU2009293444B2/en
Priority to MX2011002805A priority patent/MX2011002805A/en
Priority to PL09792531T priority patent/PL2342198T3/en
Priority to KR1020117008623A priority patent/KR101129088B1/en
Priority to EA201100501A priority patent/EA020048B1/en
Priority to JP2011527035A priority patent/JP4897938B2/en
Priority to SI200930626T priority patent/SI2342198T1/en
Priority to US13/061,572 priority patent/US8063043B2/en
Priority to CN200980144876.0A priority patent/CN102159570B/en
Priority to DK09792531.7T priority patent/DK2342198T3/en
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to CA2736751A priority patent/CA2736751C/en
Priority to UAA201103086A priority patent/UA103049C2/en
Priority to BR122020009045-6A priority patent/BR122020009045B1/en
Priority to ES09792531T priority patent/ES2418485T3/en
Publication of WO2010033481A1 publication Critical patent/WO2010033481A1/en
Priority to TN2011000092A priority patent/TN2011000092A1/en
Priority to IL211412A priority patent/IL211412A/en
Priority to ZA2011/01579A priority patent/ZA201101579B/en
Priority to CU2011000055A priority patent/CU23860B1/en
Priority to MA33778A priority patent/MA32717B1/en
Priority to US13/272,814 priority patent/US20120035174A1/en
Priority to HK11111044.0A priority patent/HK1156628A1/xx
Priority to US13/462,483 priority patent/US20120214810A1/en
Priority to SM201300072T priority patent/SMT201300072B/en
Priority to HRP20130597AT priority patent/HRP20130597T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]- 2-methyl-4'-(trifluoromethoxy)[l,r-biphenyl]-3-carboxamide, as well as to pharmaceutical compositions comprising the same and methods of treatment using the same.
  • the present invention is directed to salts of N-[6-(cis-2,6-dimethylmorpholin-4- yl)pyridine-3 -yl] -2 -methyl -4 ' -(trifluoromethoxy) [1,1' -biphenyl] -3 -carboxamide.
  • Preferred embodiments of the present invention are directed to the hydrochloride, diphosphate and sulfate salts ofN-[6-(cis-2,6-dimethylmo ⁇ holin-4-yl)pyridine-3-yl]-2-methyl-4'- (trifiuoromethoxy)[ 1,1 ' -biphenyl] -3 -carboxamide.
  • compositions comprising:
  • the present invention is also directed to a method of treating a disease which responds to modulating the activity of the hedgehog signaling pathway comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of an inventive salt of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'- (trifiuoromethoxy)[ 1 , 1 '-biphenyl] -3 -carboxamide.
  • Figure 1 shows the x-ray powder diffraction pattern for N-[6-(cis-2,6- dimethylmorpholin-4-yl)pyridine-3 -yl] -2-methyl-4 ' -(trifluoromethoxy) [1,1 ' -biphenyl] -3 - carboxamide diphosphate salt.
  • Figure 2 shows the x-ray powder diffraction pattern for N-[6-(cis-2,6- dimethylmorpholin-4-yl)pyridine-3 -yl] -2-methyl-4 ' -(trifluoromethoxy) [1,1' -biphenyl] -3 - carboxamide monosulfate salt.
  • Figure 3 shows the x-ray powder diffraction pattern for N-[6-(cis-2,6- dimethylmo ⁇ holin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[ 1 , 1 '-biphenyl]-3- carboxamide monohydrochloride salt.
  • salt refers to a compound prepared by the reaction of an organic acid or base drug with a pharmaceutically acceptable mineral or organic acid or base; as used herein, “salt” includes hydrates and solvates of salts made in accordance with this invention. Exemplary pharmaceutically acceptable mineral or organic acids or bases are as listed in Tables 1-8 in Handbook of Pharmaceutical Salts, P.H. Stahl and CG. Wermuth (eds.), VHCA, Zurich 2002, pp. 334-345.
  • salts include, but are not limited to, hydrochloride, phosphate, sulfate, mesylate, esylate and besylate salt forms.
  • polymorph refers to a distinct “crystal modification” or “polymorphic form” or “crystalline form”, which differs from another with respect to x-ray powder diffraction pattern, physico- chemical and/or pharmacokinetic properties, and thermodynamic stability.
  • An embodiment of the present invention is directed to salts of N-[6-(cis-2,6- dimethylmorpholin-4-yl)pyridine-3 -yl] -2-methyl-4 ' -(trifluoromethoxy) [1,1 ' -biphenyl] -3 - carboxamide.
  • the salt is selected from the mono hydrochloride, diphosphate and mono sulfate salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4' -(trifluoromethoxy) [1,1 '-biphenyl] -3 -carboxamide.
  • a particularly preferred embodiment of the of the present invention are the diphosphate and the mono sulfate salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[l,l'- biphenyl] -3 -carboxamide.
  • the present invention may be used for treating carcinoma including that of the bladder (including accelerated and metastatic bladder cancer), breast, colon (including colorectal cancer), kidney, liver, lung (including small and non-small cell lung cancer and lung adenocarcinoma), ovary, prostate, testes, genitourinary tract, lymphatic system, rectum, larynx, pancreas (including exocrine and endocrine pancreatic carcinoma), esophagus, stomach, gall bladder, cervix, thyroid, and skin (including squamous cell carcinoma); tumors of the central and peripheral nervous system including astrocytoma, neuroblastoma, glioma, medulloblastoma and schwannomas; tumors of mesenchymal origin including fibrosarcoma, rhabdomyosarcoma, and osteosarcoma; and other tumors including melanoma, Merkel cell carcinoma, xeroderma pigmentosum, keratoacan
  • the present invention is also useful for inhibiting the growth and proliferation of hematopoietic tumors of lymphoid lineage such as leukemia, including acute lymphocytic leukemia (ALL), acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, histiocytic lymphoma, and Burkitts lymphoma; and hematopoietic tumors of myeloid lineage including acute and chronic myelogenous leukemias (CML), myelodysplastic syndrome, myeloid leukemia, and promyelocytic leukemia.
  • ALL acute lymphocytic leukemia
  • B-cell lymphoma B-cell lymphoma
  • T-cell lymphoma T-cell lymphoma
  • Hodgkins lymphoma non-Hodgkins lymphoma
  • N-[6-(cis-2,6-dimethylmorpholin- 4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[ 1 , 1 '-biphenyl]-3-carboxamide diphosphate precipitates out.
  • the white slurry was stirred and cooled to room temp over 100 minutes.
  • the slurry was then cooled to 0 ⁇ 5°C over 5 minutes and stirred for 1 hour.
  • the mixture was filtered under suction and solid was washed with acetonitrile (3 x 9.4 mL).
  • the drug substance was dried under vacuum at 5O 0 C for 16 hours to obtain 9.63 g of the phosphate salt (yield: 98%).
  • Table 1 below shows stability measured by degradation products (or assay) and appearance color.
  • DPs are analyzed by HPLC (method see Table 3). They are calculated as area-% products.
  • Compositions of the mixtures in mass% are as follows.
  • Mixture 1 Lactose 200 mesh / maize starch modified 1500 LM / Aerosil 200 / Magnesiumstearate 78.5:20:0.5:1 (m/m/m/m).
  • Mixture 2 Mannitol / Avicel PH 102 / Cutina HR (57:38:5) (m/m/m).
  • Example 5 Table 2 below shows chemical and physico-chemical characteristics.
  • 0.1N HCl solution XRPD pattern XRPD pattern XRPD pattern changed, different changed, different changed, different than free base. than that of free than that of free base. base.
  • the inter-subject exposure is slightly variable, especially at high dose (100 mpk). See Table 4.
  • a suspension formulation of the free form and the diphosphate salt of N-[6-(cis-2,6- dimethylmorpholin-4-yl)pyridine-3 -yl] -2-methyl-4 ' -(trifluoromethoxy)[ 1,1 ' -biphenyl] -3 - carboxamide are dosed to rat at 3 mpk and 2.1 mpk, respectively. It was found that the disphosphate salt provided a large increase in exposure (16-fold increase) compared to the free form as outline in Table 5.
  • Example 9 Details about methodology, instruments and standards used in Examples 4-5
  • the pH was determined by transferring approximately 10 mg of N-[6-(cis-2,6- dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[ 1 , 1 '-biphenyl]-3- carboxamide salt to a 20 mL vial and adding 10 mL of the corresponding buffer or water. The solutions were stirred continuously as the pH was measured.
  • acetonitrile was added to dilute the 0.2% slurry to 0.1% clear solution.
  • tetrahydrofuran was added to dilute the 0.2% slurry to 0.1% clear solution.
  • acetonitrile was added to dilute the 0.2% slurry to 0.1% clear solution.
  • acetonitrile or acetonitrile/water 50:50, v/v
  • the corresponding solvent or solvent mixture was added to dilute the 0.2% slurry to 0.1% clear solution.
  • the sulfate salt and diphosphate salt of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]- 2-methyl-4'-(trifluoromethoxy)[l,r-biphenyl]-3-carboxamide are dosed as a suspension at 1 mg/mL in 0.5% Methyl Cellulose/0.5% Tween 80 at a dosing volume of 10 mL/kg to Wistar rats.
  • the diphosphate salt was found to give 1.6x more exposure in terms of AUC (0-24 hours) ng*hr/mL when compared to the sulfate salt. Results are shown below in Table 7.
  • the mean tmax for sulfate salt is shorter (2.3 hours) versus diphosphate salt (6.7 hours).
  • the mean cmax/dose for phosphate is 303 and for sulfate is 244.
  • the mean auc/dose for phosphate is 4850, for sulfate is 3030.
  • the sulfate salt showed less exposure in-vivo (about 40% less) than the diphosphate salt.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Salts of N-[6-(cis-2,6-dimethylmorpholin-4-y)pyridine-3-yl]-2-methyl-4'- (trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide are prepared and characterized.

Description

Salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'- (trifluoromethoxy) [1,1' -biphenyl] -3 -carboxamide
BACKGROUND OF THE INVENTION
Field of the Invention
[0001] This invention relates to salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]- 2-methyl-4'-(trifluoromethoxy)[l,r-biphenyl]-3-carboxamide, as well as to pharmaceutical compositions comprising the same and methods of treatment using the same.
Related Background Art
[0002] The compound N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'- (trifluoromethoxy)[l,r-biphenyl]-3-carboxamide has the formula (I):
Figure imgf000003_0001
(I) as described in WO 2007/131201. Valuable pharmacological properties are attributed to this compound; thus, it can be used, for example, as modulating the activity of the hedgehog signaling pathway useful in therapy for diseases which respond to modulating the activity of the hedgehog signaling pathway. WO 2007/131201 does not disclose any specific salts or salt hydrates or solvates of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'- (trifluoromethoxy)[l,r-biphenyl]-3-carboxamide. [0003] It has been found that the salt forms of the present invention shows that in addition to good physico-chemical properties that salts may have high permeability and high bioavailability.
SUMMARY OF THE INVENTION
[0004] The present invention is directed to salts of N-[6-(cis-2,6-dimethylmorpholin-4- yl)pyridine-3 -yl] -2 -methyl -4 ' -(trifluoromethoxy) [1,1' -biphenyl] -3 -carboxamide. Preferred embodiments of the present invention are directed to the hydrochloride, diphosphate and sulfate salts ofN-[6-(cis-2,6-dimethylmoφholin-4-yl)pyridine-3-yl]-2-methyl-4'- (trifiuoromethoxy)[ 1,1 ' -biphenyl] -3 -carboxamide.
[0005] The invention is further directed to pharmaceutical compositions comprising:
(a) a therapeutically effective amount of an inventive salt of N-[6-(cis-2,6- dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[l,r-biphenyl]-3- carboxamide; and
(b) at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient.
[0006] The present invention is also directed to a method of treating a disease which responds to modulating the activity of the hedgehog signaling pathway comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of an inventive salt of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'- (trifiuoromethoxy)[ 1 , 1 '-biphenyl] -3 -carboxamide.
BRIEF DESCRIPTION OF THE DRAWINGS
[0007] Figure 1 shows the x-ray powder diffraction pattern for N-[6-(cis-2,6- dimethylmorpholin-4-yl)pyridine-3 -yl] -2-methyl-4 ' -(trifluoromethoxy) [1,1 ' -biphenyl] -3 - carboxamide diphosphate salt.
[0008] Figure 2 shows the x-ray powder diffraction pattern for N-[6-(cis-2,6- dimethylmorpholin-4-yl)pyridine-3 -yl] -2-methyl-4 ' -(trifluoromethoxy) [1,1' -biphenyl] -3 - carboxamide monosulfate salt. [0009] Figure 3 shows the x-ray powder diffraction pattern for N-[6-(cis-2,6- dimethylmoφholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[ 1 , 1 '-biphenyl]-3- carboxamide monohydrochloride salt.
DETAILED DESCRIPTION OF THE INVENTION
[0010] As used herein, "salt" refers to a compound prepared by the reaction of an organic acid or base drug with a pharmaceutically acceptable mineral or organic acid or base; as used herein, "salt" includes hydrates and solvates of salts made in accordance with this invention. Exemplary pharmaceutically acceptable mineral or organic acids or bases are as listed in Tables 1-8 in Handbook of Pharmaceutical Salts, P.H. Stahl and CG. Wermuth (eds.), VHCA, Zurich 2002, pp. 334-345. In particular, salts include, but are not limited to, hydrochloride, phosphate, sulfate, mesylate, esylate and besylate salt forms. As used herein, "polymorph" refers to a distinct "crystal modification" or "polymorphic form" or "crystalline form", which differs from another with respect to x-ray powder diffraction pattern, physico- chemical and/or pharmacokinetic properties, and thermodynamic stability.
[0011] An embodiment of the present invention is directed to salts of N-[6-(cis-2,6- dimethylmorpholin-4-yl)pyridine-3 -yl] -2-methyl-4 ' -(trifluoromethoxy) [1,1 ' -biphenyl] -3 - carboxamide. In preferred embodiments, the salt is selected from the mono hydrochloride, diphosphate and mono sulfate salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4' -(trifluoromethoxy) [1,1 '-biphenyl] -3 -carboxamide. A particularly preferred embodiment of the of the present invention are the diphosphate and the mono sulfate salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[l,l'- biphenyl] -3 -carboxamide.
[0012] The present invention may be used for treating carcinoma including that of the bladder (including accelerated and metastatic bladder cancer), breast, colon (including colorectal cancer), kidney, liver, lung (including small and non-small cell lung cancer and lung adenocarcinoma), ovary, prostate, testes, genitourinary tract, lymphatic system, rectum, larynx, pancreas (including exocrine and endocrine pancreatic carcinoma), esophagus, stomach, gall bladder, cervix, thyroid, and skin (including squamous cell carcinoma); tumors of the central and peripheral nervous system including astrocytoma, neuroblastoma, glioma, medulloblastoma and schwannomas; tumors of mesenchymal origin including fibrosarcoma, rhabdomyosarcoma, and osteosarcoma; and other tumors including melanoma, Merkel cell carcinoma, xeroderma pigmentosum, keratoacanthoma, seminoma, thyroid follicular cancer, and teratocarcinoma. The present invention may also be used for treating mastocytosis, germ cell tumors, pediatric sarcomas, and other cancers.
[0013] The present invention is also useful for inhibiting the growth and proliferation of hematopoietic tumors of lymphoid lineage such as leukemia, including acute lymphocytic leukemia (ALL), acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, histiocytic lymphoma, and Burkitts lymphoma; and hematopoietic tumors of myeloid lineage including acute and chronic myelogenous leukemias (CML), myelodysplastic syndrome, myeloid leukemia, and promyelocytic leukemia.
Example 1
Preparation of the diphosphate salt
[0014] To a 250 mL, three-necked reaction flask 7.0 g (0.0144 mole) of 2-methyl-4'- trifluoromethoxy-biphenyl-3-carboxylic acid [6-(cis-2,6-dimethyl-morpholin-4-yl)-pyridin-3- yl]-amide free base and acetonitrile (178.5 mL, HPLC grade) was added under nitrogen. The suspension was heated to 58°C under nitrogen over 20 minutes to obtain a clear solution. To the reaction solution 3.403 g of 85% phosphoric acid in water (2 equiv) was added over 18 minutes. Within 5 minutes of the phosphoric acid addition, N-[6-(cis-2,6-dimethylmorpholin- 4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[ 1 , 1 '-biphenyl]-3-carboxamide diphosphate precipitates out. The white slurry was stirred and cooled to room temp over 100 minutes. The slurry was then cooled to 0 ± 5°C over 5 minutes and stirred for 1 hour. The mixture was filtered under suction and solid was washed with acetonitrile (3 x 9.4 mL). The drug substance was dried under vacuum at 5O0C for 16 hours to obtain 9.63 g of the phosphate salt (yield: 98%). Example 2
Preparation for the monosulfate salt
[0015] To a 100 mL, three-necked reaction flask was charged 3.0 g (6.18 mmole) of N-[6- (cis-2,6-dimethylmoφholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[l,r- biphenyl]-3-carboxamide free base and acetonitrile (35 mL, HPLC grade) under nitrogen. The suspension was heated to 50°C under nitrogen over 30 minutes to obtain a clear solution. To the mixture was added a 1.5 mL of 6 M sulfuric acid (1.5 equiv) over 10 minutes. The mixture was stirred at 50°C for 3 hours and allowed to cool to 25°C over 25 minutes. Within 5 minutes the solids came out. The slurry was stirred at 25°C for 16 hours. The mixture was filtered under suction and solid was washed with acetonitrile (10 mL). The drug substance was dried under vacuum at 55°C for 16 hours to obtain 3.0 g of the sulfate salt (yield: 83%).
Example 3
Preparation for the monohydrochloride salt
[0016] To a 100 mL, three-necked reaction flask was charged 3.0 g (6.18 mmole) of N- [6- (cis-2,6-dimethylmoφholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[ 1,1 '- biphenyl]-3-carboxamide free base and acetone (25 mL, HPLC grade) under nitrogen. The suspension was stirred at 250C under nitrogen for 30 minutes to obtain a clear solution. To the mixture was added a 1.5 mL of 6 M hydrochloric acid (1.5 equiv) over 10 minutes. Within 5 minutes the solids came out. The slurry was stirred at 250C for 16 hours. The mixture was filtered under suction and solid was washed with acetone (10 mL). The drug substance was dried under vacuum at 55°C for 16 hours to obtain 3.0 g of the hydrogen chloride salt (yield: 93%). Example 4
Table 1 below shows stability measured by degradation products (or assay) and appearance color. DPs are analyzed by HPLC (method see Table 3). They are calculated as area-% products. Compositions of the mixtures in mass% are as follows. Mixture 1 : Lactose 200 mesh / maize starch modified 1500 LM / Aerosil 200 / Magnesiumstearate 78.5:20:0.5:1 (m/m/m/m). Mixture 2: Mannitol / Avicel PH 102 / Cutina HR (57:38:5) (m/m/m).
Figure imgf000008_0001
Unstressed drug substance
Bulk 1.02 0.42 0.30
0.2 % solutions or suspensions, 2 week 50°C
Figure imgf000008_0002
2% (or 5%) solutions or suspensions, 1 day room temperature
Figure imgf000008_0003
Solid state, 2 week 50°C, tight container
Bulk (HPLC) 1.03 A 0.40 0.31
Figure imgf000009_0001
Solid state, 2 week 80 0C, tight container
Bulk (HPLC) 1.06 A 0.43 A 0.35 A
Bulk (DSC) No - No - No - change change change
2 weeks 50°C, tight container
1% in mixture 1 0 .96 A 0.41 A 0.27 A
1% in mixture 2 1 .11 A 0.44 A 0.39 A
Figure imgf000009_0002
Figure imgf000009_0003
2 weeks 50°C/ 75% r.h.
Figure imgf000009_0004
Xenon light (approx. 1200 1 cLuxh)
Bulk (HPLC) 1.35 A 1.1 A 1.46 B
Bulk (XRPD) No - No - No - change change change
Bulk corrosivity
2 day 80% r.h. with No visible change No visible change No visible change stainless steel coupon in the surface of in the surface of in the surface of the stainless steel the stainless steel the stainless steel coupon coupon coupon
* There is a new peak in the XRPD pattern when compared with the unstressed diphosphate. ** The XRPD pattern is similar to that of phosphate, yet with one extra peak. 4- Suspension * Clear solution after stress test
- Test not performed A No change of color
B Slight discoloration C Medium discoloration
D Strong discoloration
Example 5 Table 2 below shows chemical and physico-chemical characteristics.
Table 2
Figure imgf000010_0001
Salt Form
Phosphate, di Sulfate, mono Hydrochloride,
Parameter mono
Phosphate buffer, pH 6.8 0.001 (Final pH 0.002 (Final pH 0.000 (Final pH 2.86) 1.82) 5.93)
Water 0.009 (Final pH 0.007 (Final pH 0.005 (Final pH 1.94) 1.26) 1.67)
Methanol >40 24.4 >40
Ethanol 19.7 19.7 56.4
2- Propanol 14.3 4 10.3
Acetone 2.8 1.7 3.2
Ethyl Acetate 0.3 0.09 2.5
Acetonitrile 0.4 1.4 4.1
Figure imgf000011_0001
NMR Chemical shift Chemical shift Chemical shift changed changed changed
* Attempts to measure intrinsic dissolution rate were not successful due to low solubility.
Example 6
Table 3 below shows morphic properties.
Table 3
Salt form
Hydrochloride,
Parameter Phosphate, di Sulfate, mono mono
Thermal properties
As is
- DSC 2130C N/A N/A
- XRPD (crystallinity) Crystalline Crystalline Crystalline
After heating and cooling-
- DSC N/A N/A N/A
- XRPD N/A N/A N/A
Hygroscopicity
Figure imgf000012_0001
Crystal modification after 72 hours vibration
DSC/XRPD/TG DSC/XRPD/TG DSC/XRPD/TG
Water XRPD pattern Dissociated to free Dissociated to free changed, different base. base than free base. Final pH 1.26 Final pH 1.94 Final pH 1.94 Salt form
Hydrochloride,
Parameter Phosphate, di Sulfate, mono mono pH 6.8 buffer XRPD pattern Dissociated to free No form change changed, different base Final pH 5.93 than free base. Final pH 1.82
Final pH 2.86
pH 3 buffer XRPD pattern Dissociated to free Dissociated to free changed, different base base than free base. Final pH 2.00 Final pH 2.89
Final pH 2.15
0.1N HCl solution XRPD pattern XRPD pattern XRPD pattern changed, different changed, different changed, different than free base. than that of free than that of free base. base.
Methanol - Y, crystalline to - crystalline
Ethanol XRPD pattern N, no form change N, no form change changed, poorer crystalline than the original.
Iso Propanol N, no form change N, no form change N, no form change
Ethyl acetate N, no form change N, no form change N, no form change
Acetone Y, crystalline to
N, no form change crystalline N, no form change
Acetonitrile N, no form change N, no form change N, no form change
Effect of grinding
No change in No change in No change in XRPD XRPD XRPD
Effect of compression
No change in No change in No change in XRPD XRPD XRPD
N - no, Y - yes Example 7
[0017] Rat TK data of N-[6-(cis-2,6-dimethylmoipholin-4-yl)pyridine-3-yl]-2-methyl-4'- (trifluoromethoxy)[l,r-biphenyl]-3-carboxamide diphosphate dosed as a suspension, with a 10-fold increase in dose, showed a 3.1 -fold increase in exposure from 10 to 100 mpk. The inter-subject exposure is slightly variable, especially at high dose (100 mpk). See Table 4.
Table 4
Figure imgf000014_0001
Example 8
[0018] A suspension formulation of the free form and the diphosphate salt of N-[6-(cis-2,6- dimethylmorpholin-4-yl)pyridine-3 -yl] -2-methyl-4 ' -(trifluoromethoxy)[ 1,1 ' -biphenyl] -3 - carboxamide are dosed to rat at 3 mpk and 2.1 mpk, respectively. It was found that the disphosphate salt provided a large increase in exposure (16-fold increase) compared to the free form as outline in Table 5.
Table 5
Figure imgf000015_0001
Example 9 Details about methodology, instruments and standards used in Examples 4-5
1 pH value
The pH was determined by transferring approximately 10 mg of N-[6-(cis-2,6- dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[ 1 , 1 '-biphenyl]-3- carboxamide salt to a 20 mL vial and adding 10 mL of the corresponding buffer or water. The solutions were stirred continuously as the pH was measured.
2 Determination of approximate solubility
Excess salts were equilibrated in solvents for 1 day at 25 ± 0.5°C. Slurries were filtered and the filtrate saved for HPLC solubility determination.
3 Hygroscopicity
Sorption/desorption isotherms: Instrument, Surface Measurement System DVS-I temperature at 25± 0.5°C.
4 Polymorphism behavior Slurries ofN-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'- (trifluoromethoxy)[l,l '-biphenyl]-3-carboxamide salts were stirred at high speed for 24 hours at 25± 0.5°C. The slurries were filtered and the solids collected for XRPD analyses.
5 HPLC Method
Column: Symmetry Cl 8, 3.5 micrometer particle diameter, 4.6 x 75mm (Waters)
Column temperature: 35 degrees
Flow rate: 1 mL/min
Mobile phase: A = 0.1% TFA in water, and B - acetonitrile
Gradient table shown below in Table 6:
Table 6
Figure imgf000016_0001
Stability sample preparation for HPLC analysis:
For phosphate in pH 1 buffer solution, acetonitrile was added to dilute the 0.2% slurry to 0.1% clear solution. For phosphate in the rest of buffer solutions, tetrahydrofuran was added to dilute the 0.2% slurry to 0.1% clear solution. For salts in water, acetonitrile was added to dilute the 0.2% slurry to 0.1% clear solution. For salts in methanol, acetonitrile or acetonitrile/water (50:50, v/v), the corresponding solvent or solvent mixture was added to dilute the 0.2% slurry to 0.1% clear solution. For salts in 0.5% CMC, HPMC cellulose 4000 0.5%, or Tween 80, 0.8%, tetrahydrofuran and water were added to dilute the 2% slurry to 0.1% clear solution and to reach tetrahydrofuran/water 50:50 (v/v). For bulk stability samples (including the samples in excipient mixtures), acetonitrile/water (80:20, v/v) was added to make 0.1% clear solution. Example 10
The sulfate salt and diphosphate salt of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]- 2-methyl-4'-(trifluoromethoxy)[l,r-biphenyl]-3-carboxamide (Compound A in Table 7 below) are dosed as a suspension at 1 mg/mL in 0.5% Methyl Cellulose/0.5% Tween 80 at a dosing volume of 10 mL/kg to Wistar rats. The diphosphate salt was found to give 1.6x more exposure in terms of AUC (0-24 hours) ng*hr/mL when compared to the sulfate salt. Results are shown below in Table 7.
Table 7
Compound Dose Rat AUC0-24 AUC0-24 Cmax/Dose
Q
(mg/ (ng*h/mL) /dose (ng*h/mL) / max (ng/mL)/ tmax (h)
(ng/mL) kg) (mg/kg/day) (mg/kg/day)
Compound A 10 1b 25900 2590 1900 190 4 Sulfate
2b 28700 2870 1860 190 2
3b 36200 3620 3560 360 1
Compound A 10 001 43300 4330 2820 282 8
Diphosphate
002 52800 5280 3160 316 8
003 49400 4940 3100 310 4
As shown in Table 7, the mean tmax for sulfate salt is shorter (2.3 hours) versus diphosphate salt (6.7 hours). The mean cmax/dose for phosphate is 303 and for sulfate is 244. The mean auc/dose for phosphate is 4850, for sulfate is 3030. Overall, the sulfate salt showed less exposure in-vivo (about 40% less) than the diphosphate salt.
[0019] While the invention has been described above with reference to specific embodiments thereof, it is apparent that many changes, modifications, and variations can be made without departing from the inventive concept disclosed herein. Accordingly, it is intended to embrace all such changes, modifications, and variations that fall within the spirit and broad scope of the appended claims. All patent applications, patents, and other publications cited herein are incorporated by reference in their entirety.

Claims

WHAT IS CLAIMED 1 S:
1. A salt of N-[6-(cis-2,6-dimethylmoipholin-4-yl)pyridine-3-yl]-2-methyl-4'- (trifluoromethoxy)[ 1 , 1 '-biphenyl]-3-carboxamide.
2. The salt of Claim 1, wherein the salt is a mono hydrochloride salt of N-[6-(cis-2,6- dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[l,r-biphenyl]-3- carboxamide.
3. The salt of Claim 1, wherein the salt is a diphosphate salt of N-[6-(cis-2,6- dimethylmorpholin-4-yl)pyridine-3 -yl] -2-methyl-4 ' -(trifluoromethoxy) [1,1 ' -biphenyl] -3 - carboxamide.
4. The salt of Claim 1 , wherein the salt is a mono sulfate salt of N-[6-(cis-2,6- dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[l,r-biphenyl]-3- carboxamide.
5. A pharmaceutical composition comprising:
(a) a therapeutically effective amount of a salt according to any one of Claims 1-4; and
(b) at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient.
6. A method of treating a disease which responds to an inhibition of protein kinase activity comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a salt according to any one of Claims 1-4.
PCT/US2009/056918 2008-09-17 2009-09-15 Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide WO2010033481A1 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
ES09792531T ES2418485T3 (en) 2008-09-17 2009-09-15 Diphosphate salt of N- [6- (cis-2,6-dimethylmorpholin-4-yl) -pyridin-3-yl] -2-methyl-4¿- (trifluoromethoxy) - [1,1¿-biphenyl] - 3-carboxamide
UAA201103086A UA103049C2 (en) 2008-09-17 2009-09-15 Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
CA2736751A CA2736751C (en) 2008-09-17 2009-09-15 Salts of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
AU2009293444A AU2009293444B2 (en) 2008-09-17 2009-09-15 Salts of N-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'- (trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
NZ591420A NZ591420A (en) 2008-09-17 2009-09-15 Salts of n-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
PL09792531T PL2342198T3 (en) 2008-09-17 2009-09-15 A diphosphate salt of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
KR1020117008623A KR101129088B1 (en) 2008-09-17 2009-09-15 Salts of n-[6-cis-2,6-dimethylmorpholin-4-ylpyridine-3-yl]-2-methyl-4'-trifluoromethoxy[1,1'-biphenyl]-3-carboxamide
EA201100501A EA020048B1 (en) 2008-09-17 2009-09-15 Diphosphate salt of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-diphenyl]-3-carboxamide and pharmaceutical composition
JP2011527035A JP4897938B2 (en) 2008-09-17 2009-09-15 N- [6- (cis-2,6-dimethylmorpholin-4-yl) pyridin-3-yl] -2-methyl-4 ′-(trifluoromethoxy) [1,1′-biphenyl] -3-carboxamide Salt
SI200930626T SI2342198T1 (en) 2008-09-17 2009-09-15 A diphosphate salt of n-s6-cis-2,6-dimethylmorpholin-4yl)pyridine-3ylc-2-methyl-4'-(trifluoromethoxy)s1,1'-biphenylc-3-carboxamide
US13/061,572 US8063043B2 (en) 2008-09-17 2009-09-15 Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide
BR122020009045-6A BR122020009045B1 (en) 2008-09-17 2009-09-15 USE OF N-[6-CIS-2,6-DIMETHYLMORPHOLIN-4-YL]PYRIDINE-3-YL]-2-METHYL-4'-(TRIFLUORMETOXY)[1,1'-BIPHENYL]-3-CARBOXAMIDE SALTS IN THE TREATMENT OF CARCINOMA AND OTHER TUMORS
DK09792531.7T DK2342198T3 (en) 2008-09-17 2009-09-15 Diphosphate salt of N- [6- (cis-2,6-dimethylmorpholin-4-yl) pyridin-3-yl] -2-methyl-4 '- (trifluoromethoxy) - [1,1'-biphenyl] -3-carboxamide
BRPI0918629A BRPI0918629B8 (en) 2008-09-17 2009-09-15 n-[6-cis-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1-1'-biphenyl]-3-carboxamide salt, and pharmaceutical composition
EP09792531A EP2342198B1 (en) 2008-09-17 2009-09-15 A diphosphate salt of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
MX2011002805A MX2011002805A (en) 2008-09-17 2009-09-15 Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methy l-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide.
CN200980144876.0A CN102159570B (en) 2008-09-17 2009-09-15 Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
IL211412A IL211412A (en) 2008-09-17 2011-02-24 Diphosphate salt of n-[6-cis-2,6-dimethylmorpholin-4yl) pyridine-3yl]-2-methyl-4'-(trifluoromethoxy) [1,1'-biphenyl]-3-carboxamide and pharmaceutical compositions comprising the same
TN2011000092A TN2011000092A1 (en) 2009-09-15 2011-02-24 Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
ZA2011/01579A ZA201101579B (en) 2008-09-17 2011-03-01 Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
CU2011000055A CU23860B1 (en) 2008-09-17 2011-03-15 SALTS OF N- [6- (CIS-2,6-DIMETIL-MORFOLIN-4-IL) -PIRIDIN-3-IL] -2-METHYL-4 '- (TRIFLUORO-METOXI) - [1,1'-BIFENIL ] -3-CARBOXAMIDA
MA33778A MA32717B1 (en) 2008-09-17 2011-04-15 N- [6-CIS- (2,6-DIMETHYLMORPHOLIN-4-YL) PYRIDIN-3-YL) -2-METHYL-4'- (TRIFLUOROMETHOXY) - [1,1'-BIPHENYL] -3-CARBOXAMIDE SALTS
US13/272,814 US20120035174A1 (en) 2008-09-17 2011-10-13 Salts of N-[6-cis-2,6-Dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
HK11111044.0A HK1156628A1 (en) 2008-09-17 2011-10-17
US13/462,483 US20120214810A1 (en) 2008-09-17 2012-05-02 Salts of N-[6-cis-2,6-Dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
SM201300072T SMT201300072B (en) 2008-09-17 2013-06-26 N- [6- (cis-2,6-dimethylmorfolin-4-yl) pyridin-3-yl] diphosphate salt -2-methyl-4 '- (tri-fluoromethoxy) [1,1'-bifenyl] -3 -carbossammide
HRP20130597AT HRP20130597T1 (en) 2008-09-17 2013-06-27 A diphosphate salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9758008P 2008-09-17 2008-09-17
US61/097,580 2008-09-17

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/061,572 A-371-Of-International US8063043B2 (en) 2008-09-17 2009-09-15 Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide
US13/272,814 Division US20120035174A1 (en) 2008-09-17 2011-10-13 Salts of N-[6-cis-2,6-Dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide

Publications (1)

Publication Number Publication Date
WO2010033481A1 true WO2010033481A1 (en) 2010-03-25

Family

ID=41228716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/056918 WO2010033481A1 (en) 2008-09-17 2009-09-15 Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide

Country Status (39)

Country Link
US (3) US8063043B2 (en)
EP (1) EP2342198B1 (en)
JP (2) JP4897938B2 (en)
KR (2) KR101129088B1 (en)
CN (1) CN102159570B (en)
AR (2) AR073591A1 (en)
AU (1) AU2009293444B2 (en)
BR (2) BR122020009045B1 (en)
CA (1) CA2736751C (en)
CL (1) CL2011000551A1 (en)
CO (1) CO6351744A2 (en)
CR (1) CR20110126A (en)
CU (1) CU23860B1 (en)
DK (1) DK2342198T3 (en)
DO (1) DOP2011000082A (en)
EA (1) EA020048B1 (en)
EC (1) ECSP11010985A (en)
ES (1) ES2418485T3 (en)
GE (1) GEP20125592B (en)
HK (1) HK1156628A1 (en)
HN (1) HN2011000745A (en)
HR (1) HRP20130597T1 (en)
IL (1) IL211412A (en)
JO (1) JO2889B1 (en)
MA (1) MA32717B1 (en)
MX (1) MX2011002805A (en)
MY (1) MY151100A (en)
NI (1) NI201100051A (en)
NZ (1) NZ591420A (en)
PE (1) PE20110292A1 (en)
PL (1) PL2342198T3 (en)
PT (1) PT2342198E (en)
SI (1) SI2342198T1 (en)
SM (1) SMT201300072B (en)
SV (1) SV2011003857A (en)
TW (1) TWI367883B (en)
UA (1) UA103049C2 (en)
WO (1) WO2010033481A1 (en)
ZA (1) ZA201101579B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014128661A1 (en) * 2013-02-25 2014-08-28 Novartis Ag Oral formulation and suspension of an oncology drug
WO2015092720A1 (en) * 2013-12-19 2015-06-25 Novartis Ag Metabolites of sonidegib (lde225)
WO2017157825A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2017163258A1 (en) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Process for the preparation of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4'-(trifiuoromethoxy) [1,1' -biphenyi]-3-carboxamide and its polymorphs thereof
EP3279198A4 (en) * 2015-03-30 2018-09-05 Crystal Pharmatech Co., Ltd. Crystal form of n-[6-(cis form-2,6-dimethylmorpholine-4-group)pyridine-3- group]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3- formamide monophosphate, and preparation method therefor

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (en) 2006-12-28 2014-04-11 Infinity Discovery Inc Cyclopamine analogs
CN101993415B (en) * 2010-09-15 2013-08-14 北京韩美药品有限公司 Compound as Hedgehog path inhibitor, medicine composition containing same and application thereof
JP6796638B2 (en) 2015-06-04 2020-12-09 ペレファーム, インク.Pellepharm, Inc. Topical formulations and their use for the delivery of hedgehog inhibitory compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131201A2 (en) * 2006-05-05 2007-11-15 Irm Llc Compounds and compositions as hedgehog pathway modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1670785T3 (en) * 2003-10-02 2010-10-18 Pharmacia & Upjohn Co Llc Salts and polymorphic forms of a pyrrole-substituted indolinone compound
GB0412468D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
PE20080948A1 (en) * 2006-07-25 2008-09-10 Irm Llc IMIDAZOLE DERIVATIVES AS MODULATORS OF THE HEDGEHOG PATH

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131201A2 (en) * 2006-05-05 2007-11-15 Irm Llc Compounds and compositions as hedgehog pathway modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Salts", 2002, VHCA, pages: 334 - 345

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014128661A1 (en) * 2013-02-25 2014-08-28 Novartis Ag Oral formulation and suspension of an oncology drug
AU2014220339B2 (en) * 2013-02-25 2016-12-01 Sun Pharmaceutical Industries Limited Oral formulation and suspension of an oncology drug
US9943520B2 (en) 2013-02-25 2018-04-17 Sun Pharma Global Fze Oral formulation and suspension of an oncology drug
US10426781B2 (en) 2013-02-25 2019-10-01 Sun Pharma Global Fze Oral formulation and suspension of an oncology drug
WO2015092720A1 (en) * 2013-12-19 2015-06-25 Novartis Ag Metabolites of sonidegib (lde225)
EP3279198A4 (en) * 2015-03-30 2018-09-05 Crystal Pharmatech Co., Ltd. Crystal form of n-[6-(cis form-2,6-dimethylmorpholine-4-group)pyridine-3- group]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3- formamide monophosphate, and preparation method therefor
US10266523B2 (en) 2015-03-30 2019-04-23 Crystal Pharmatech Co., Ltd. Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof
WO2017157825A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for use in the treatment of solid tumors
US10265279B2 (en) 2016-03-15 2019-04-23 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
WO2017163258A1 (en) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Process for the preparation of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4'-(trifiuoromethoxy) [1,1' -biphenyi]-3-carboxamide and its polymorphs thereof

Also Published As

Publication number Publication date
EA020048B1 (en) 2014-08-29
BRPI0918629B1 (en) 2021-04-13
SV2011003857A (en) 2011-05-16
NI201100051A (en) 2011-09-08
PT2342198E (en) 2013-07-10
JP2012097104A (en) 2012-05-24
IL211412A0 (en) 2011-05-31
JO2889B1 (en) 2015-03-15
PE20110292A1 (en) 2011-05-17
SI2342198T1 (en) 2013-07-31
AU2009293444B2 (en) 2012-03-15
JP2012502912A (en) 2012-02-02
EP2342198A1 (en) 2011-07-13
SMT201300072B (en) 2013-09-06
AR113778A2 (en) 2020-06-10
EP2342198B1 (en) 2013-04-03
MA32717B1 (en) 2011-10-02
JP4897938B2 (en) 2012-03-14
HRP20130597T1 (en) 2013-07-31
PL2342198T3 (en) 2013-08-30
US20110178085A1 (en) 2011-07-21
AR073591A1 (en) 2010-11-17
CO6351744A2 (en) 2011-12-20
HK1156628A1 (en) 2012-06-15
EA201100501A1 (en) 2011-10-31
US20120214810A1 (en) 2012-08-23
DOP2011000082A (en) 2011-04-15
BRPI0918629B8 (en) 2021-05-25
MY151100A (en) 2014-04-15
CU20110055A7 (en) 2011-12-28
BR122020009045A2 (en) 2020-11-10
CR20110126A (en) 2011-04-27
AU2009293444A1 (en) 2010-03-25
ES2418485T3 (en) 2013-08-14
KR101129088B1 (en) 2012-03-23
CN102159570A (en) 2011-08-17
ECSP11010985A (en) 2011-05-31
KR20110056325A (en) 2011-05-26
NZ591420A (en) 2012-07-27
TW201016686A (en) 2010-05-01
BRPI0918629A2 (en) 2020-10-27
HN2011000745A (en) 2014-01-06
CN102159570B (en) 2014-01-15
CA2736751A1 (en) 2010-03-25
KR20120015363A (en) 2012-02-21
US20120035174A1 (en) 2012-02-09
ZA201101579B (en) 2011-11-30
CA2736751C (en) 2012-10-23
CL2011000551A1 (en) 2011-07-15
US8063043B2 (en) 2011-11-22
UA103049C2 (en) 2013-09-10
DK2342198T3 (en) 2013-07-01
MX2011002805A (en) 2011-04-11
TWI367883B (en) 2012-07-11
CU23860B1 (en) 2013-02-26
BR122020009045B1 (en) 2022-08-02
IL211412A (en) 2014-07-31
GEP20125592B (en) 2012-07-25

Similar Documents

Publication Publication Date Title
CA2736751C (en) Salts of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
IL237048A (en) Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN108069959A (en) A kind of nitrogen-containing hetero cyclics, its preparation method, pharmaceutical composition and application
WO2010139980A1 (en) Process for preparing crystalline dasatinib monohydrate
CN111617083A (en) Application of methoxy-substituted phenylamide aminopyrimidine derivative
CN109384774B (en) Polysubstituted pyrazine/triazine amide compounds and preparation method and application thereof
WO2009147626A2 (en) Anhydrous amorphous form of imatinib mesylate
AU2012203520A1 (en) Salts of N-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'- (trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
CN105050602A (en) Pyridine compounds used as pi3 kinase inhibitors
CN110300587A (en) Deuterated (S) -2- (4- (piperidines -3- base) phenyl) -2H- indazole -7- formamide
EP3475269A1 (en) Solid state forms of neratinib and salts thereof
ES2881960T3 (en) Protein kinase inhibitors
WO2016187028A1 (en) Heteroaryl compounds, synthesis thereof, and intermediates thereto
Han et al. Design, synthesis and anticancer activity evaluation of 4-(3-1H-indazolyl) amino quinazoline derivatives as PAK4 inhibitors
CN105705499A (en) Process for preparing a compound
WO2017029408A1 (en) Solid state forms of sofosbuvir
CN116514832A (en) Crystal form of oxazabicyclo derivative and preparation method thereof
CN111732585A (en) Cyclic sulfonamide ring-substituted pyridone pyrrole compound and synthesis method and application thereof
KR20090060673A (en) Crystalline inorganic salt of ziprasidone, a process for the preparation thereof, and a pharmaceutical composition comprising the same
KR20090060672A (en) Crystalline inorganic salt of ziprasidone, a process for the preparation thereof, and a pharmaceutical composition comprising the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980144876.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09792531

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 211412

Country of ref document: IL

Ref document number: 2009293444

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 591420

Country of ref document: NZ

Ref document number: 1442/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 13061572

Country of ref document: US

Ref document number: 2009792531

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011527035

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12011500480

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2736751

Country of ref document: CA

Ref document number: CR2011-000126

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 000619-2011

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: D2011055

Country of ref document: CU

Ref document number: MX/A/2011/002805

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2011000551

Country of ref document: CL

ENP Entry into the national phase

Ref document number: 2009293444

Country of ref document: AU

Date of ref document: 20090915

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11036968

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: DZP2011000269

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 20117008623

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12188

Country of ref document: GE

Ref document number: 201100501

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201103086

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 12012500399

Country of ref document: PH

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0918629

Country of ref document: BR

Free format text: REAPRESENTAR, EM ATE 60 (SESSENTA) DIAS, O RELATORIO DESCRITIVO ENVIADO NA PETICAO NO 020110025085 DE 16/03/2011 CONTENDO AS PAGINAS 21 A 23, OU, CONFIRMAR SER UM ERRO DE PAGINACAO E RE-ENVIAR O CONTEUDO COM PAGINACAO CORRETA

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0918629

Country of ref document: BR

Free format text: PEDIDO RETIRADO POR NAO CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI 2577 DE 26/05/2020. FOI SOLICITADO AO DEPOSITANTE A REAPRESENTACAO DO CONTEUDO DO RELATORIO DESCRITIVO APRESENTADO NA PETICAO NO 020110025085 DE 16/03/2011, POIS O MESMO POSSUI ERRO DE PAGINACAO. O DEPOSITANTE RESPONDEU A EXIGENCIA ATRAVES DA PETICAO NO 87020069392 DE 03/06/2020 APRESENTANDO CONTEUDO DIVERGENTE DO SOLICITADO, NAO CORRESPONDENDO AO RELATORIO ORIGINALMENTE APRESENTADO E SIM A MODIFICACAO DO MESMO, TENDO, POR ISSO, NAO RESPONDIDO A EXIGENCIA FORMULADA, UMA VEZ QUE NAO ESCLARECEU A DIVERGENCIA DO NUMERO DE PAGINAS DO RELATORIO CONSTANTE NA PETICAO CITADA NEM APRESENTOU O CONTEUDO DA MESMA DEVIDAMENTE CORRIGIDO.

ENP Entry into the national phase

Ref document number: PI0918629

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110316